Clinical Trials
8 trialsNCT07446322 2026-05-05
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Oncolytics Biotech
Phase 2 Recruiting
NCT04215146 2025-01-16
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Oncolytics Biotech
Phase 2 Active not recruiting
NCT00998192 2016-03-31
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00861627 2015-12-02
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Oncolytics Biotech
Phase 2 Completed
NCT00984464 2015-04-10
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Oncolytics Biotech
Phase 2 Completed
NCT00998322 2015-04-10
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 2 Completed
NCT00753038 2014-11-04
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Oncolytics Biotech
Phase 2 Completed
NCT00503295 2014-10-02
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Oncolytics Biotech
Phase 2 Completed